Press

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

Mar 10 • 5 min read

Key Highlights: Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of Matter patent protection in the UK, moves towards Phase I clinical trial in H2 2022 on positive preclinical data Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF)…

Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder

Mar 9 • 2 min read

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, is pleased to conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. Today the Company completed first patient randomization at its Draper, Utah research site. “The Psilocybin Trial…

Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration

Mar 8 • 3 min read

Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced a Collaboration agreement with SciSparc Ltd. (NASDAQ: SPRC). The two companies will explore the potential for the creation of innovative compounds in the psychedelic area….

Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update

Mar 7 • 5 min read

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year-end 2021 business and clinical update. “In the second half of 2021, we continued to accomplish several significant milestones and continued to execute in the face of one of the…

Magellan Rx Management Releases Clinical Insights on the Use of Psychedelics in Treating Mental Health Conditions

Mar 4 • 3 min read

Magellan Rx Management, the full-service pharmacy benefits management division of Magellan Health, Inc. today released its Clinical Insights publication titled Therapeutic Psychedelics: an Emerging Frontier in Mental Health. The paper explores the role of psychedelics in treating mental health conditions, the current regulatory and legislative landscape, and Magellan Rx Management’s four-pillar evaluation on this emerging therapeutic frontier. Although psychedelics…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435